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Background: Acute septicemic melioidosis is associated with systemic release of
endotoxin and the proinflammatory cytokines tumor necrosis factor (TNF)-alpha,
interleukin-1, and interleukin-6. Excessive release of these cytokines may lead to
endothelial injury, depletion of naturally occurring endothelial modulators, micro-
vascular thrombosis, organ failure, and death.
Method: Plasma samples drawn at baseline and after initial antimicrobial therapy in
30 patients with suspected acute severe melioidosis were assayed for D-dimer levels,
protein C and protein S antigen levels, and antithrombin functional activities.§ Presented in part at the 20th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 2000
(abstract P 30).
* Corresponding author. Tel.: +1 401 444 6315; fax: +1 401 444 8154.
E-mail addresses: slarosa@lifespan.org (S.P. LaRosa), steven_opal@brown.edu (S.M. Opal).
1201-9712/$32.00 # 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2005.06.001
26 S.P. LaRosa et al.Results: Both baseline and continued deficiencies of protein C, protein S, and
antithrombin were statistically associated with a poor outcome by logistic regression.
Baseline D-dimer levels were significantly higher in fatal cases than survivors and
correlated inversely with protein C and antithrombin, suggesting both increased fibrin
deposition and fibrinolysis.
Conclusion: The inflammatory response to systemic Burkholderia pseudomallei infec-
tion leads to depletion of the natural endothelial modulators protein C, protein S, and
antithrombin. Both baseline and continued deficiency of these endothelial modula-
tors is predictive of poor outcome in melioidosis.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Melioidosis is an infection caused by the organism
Burkholderia pseudomallei, a small, motile, Gram-
negative, non-spore-forming obligate aerobe found
in soil and surface water, e.g., rice paddies in ende-
mic areas.1 Infection with this organism can occur by
direct inoculation, inhalation, aspiration, or inges-
tion.2 The clinical presentation of melioidosis
includes fever of unknown etiology, localized skin/
soft tissue abscess, pneumonia, and septicemia.3 In
Northeast Thailand, melioidosis is the most common
cause of septicemia during the rainy season.4 The
disease therefore provides an ideal opportunity to
study many cases of Gram-negative sepsis caused by
a single organism, in a homogeneous population, and
at a single study site, thus bypassing many of the
problems that beset other sepsis studies.5
Sepsis irrespective of microbiologic cause is asso-
ciated with the interplay of inflammation and coa-
gulation. Experimental studies have shown that
endotoxin, as well as the proinflammatory cytokines
tumor necrosis factor (TNF)-alpha, interleukin-1
(IL-1), and interleukin-6 (IL-6) can lead to activation
of the extrinsic pathway of coagulation by causing
the expression of tissue factor on the endothelium
and monocytes.6,7 High circulating levels of endo-
toxin, TNF and IL-6 have each been demonstrated in
melioidosis patients.8,9
Three endogenous anticoagulants that regulate
the inflammatory and coagulation cascade in sepsis
are activated protein C (APC), antithrombin and
protein S. Activated protein C is generated from
the inactive zymogen protein C in the setting of
thrombin production. It inhibits factor V thereby
preventing further thrombin generation, restores
fibrinolysis by inactivating plasminogen activator
inhibitor (PAI-1) and has anti-inflammatory pro-
perties.10—14 Antithrombin is a serine protease inhi-
bitor that inactivates multiple clotting enzymes
(Xa, IXa, XIa) and, in particular, thrombin by form-
ing thrombin—antithrombin complexes (TAT).15
Antithrombin too has distinct anti-inflammatoryproperties.16 Protein S is the third endothelial mod-
ulator that may be affected in the septic state.
Protein S is a vitamin K-dependent protein that has
no enzymatic activity of its own. This molecule
enhances the activity of APC by inhibiting the pro-
tective effect of factor Xa on factor Va, thereby
making factor Va more susceptible to cleavage by
APC.17 Severe sepsis can lead to the decreased pro-
duction, increased consumption and inhibition of
these endogenous anticoagulants.18
In this study we measured levels of protein C,
protein S, and antithrombin in a homogeneous group
of patients with suspected acute severe melioidosis,
to assess if early and continued deficiency of these
endothelial modulators of coagulation and inflam-
mation is predictive of a poor outcome. D-dimer
levels were measured to assess if fibrin deposition
and lysis were predictive of outcome. Finally, we
attempted to correlate levels of these endothelial




A subset of samples from patients with suspected
acute severe Burkholderia pseudomallei infections
enrolled in a prospective, randomized treatment
trial of high-dose intravenous imipenem versus cef-
tazidime, conducted at Sappasitprasong Hospital in
Northeast Thailand, was randomly selected to eval-
uate retrospectively biomarker levels of protein C,
protein S, antithrombin, and D-dimer in acute
severe melioidosis. Ethical approval for the trial
was received from the Ethical and Scientific Sub-
committee of the Thai Ministry of Public Health. The
trial enrolled 296 patients with suspected melioi-
dosis between July 1994 and November 1997. The
results indicated no statistical significance in the
difference in mortality between the two treatment
groups ( p = 0.96).19
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Venous blood samples from patients with acute sep-
ticemic melioidosis were collected in heparinized
tubes atbaselineandat timesup to24 hafter starting
antimicrobial therapy. Plasma was separated imme-
diately and stored at 70 8C until assays were per-
formed. Before assay, the plasma samples were
thawed for 10 min at 37 8C and then placed on ice.
Assay methods
The investigators randomly selected plasma samples
from 30 patients with suspected acute septicemic
melioidosis to send to Lilly Research Laboratories for
analysis of the biomarkers. The Lilly group was
blinded to patient outcome.
Protein C antigen
Total protein C antigen levels in the heparinized
plasma were measured with a commercially avail-
able antigen assay Asserachrom Protein C (Stago
Diagnostica, Asnieres, France) following the manu-
facturer’s instructions. This sandwich-based ELISA
uses rabbit antihuman protein C F(ab) 2 fragments
as the capture antibody. The normal range of pro-
tein C antigen in 30 normal plasmas was 73.7—140%.
Protein S antigen
Free protein S antigen levels were measured with a
commercially available antigen assay, Asserachrom
Protein S (Stago Diagnostica, Asnieres, France) fol-
lowing the manufacturer’s instructions. The normal
range of free protein S antigen in 30 normal plasmas
was 55—116%.
Antithrombin activity
Activity levels were measured with a commercially
available assay, Stachrom AT III (Stago Diagnostica,
Asnieres, France). The chromogenic activity was
measured with the Stago Compact Coagulation Ana-
lyzer. The normal range of antithrombin activity
established in 30 normal plasmas was 86—124%.
D-dimer
D-dimer levels were quantified by a latex immunoas-
say method using Liatest D-DI (Diagnostica Stago,
Asnieres, France). The increase in absorbance at
540 nm due to binding of D-dimer to the antibody-
coated latex beads was measured with the Stago
Compact Coagulation Analyzer. The normal range
established for this assay was 0.05—0.47 mg/mL.Cytokine data, demographics, and
baseline characteristics
Baseline demographic, clinical and laboratory char-
acteristics of the patients in this study were
recorded on admission. IL-6 data have been pub-
lished previously.9,19
Statistical methods
Results of samples drawn during the illness were
averaged for each patient. Assay data were ana-
lyzed with patient demographic information and
outcomes. ANOVA analyses were performed to com-
pare baseline values of the biomarkers protein C
antigen, protein S antigen, antithrombin functio–
nal activity, and D-dimer in survivors and fatal cases.
A logistic regression procedure was performed to
assess if the baseline and averaged values of the
biomarkers during the illness were predictive of
survival. Associations of the biomarkers were tested
by Spearman’s rank correlation coefficient. A fitted
logistic regression model was used to construct a
probability of survival curve based on protein C
levels and antithrombin levels. A probability
<0.05 was considered statistically significant.Results
Samples from 30 patients with suspected acute
severe melioidosis were analyzed in this study. B.
pseudomalleiwas subsequently isolated from clinical
samples from 28 patients; two patients were culture-
negative and thus not proven to have melioidosis. A
large percentage of the patients were bacteremic,
and the lung was the common site of focal infection.
Themortality rate,measured as in-hospitalmortality
or when the patient was taken home moribund, was
40% (12/30). The demographics and baseline charac-
teristics of survivors and fatal cases are presented in
Table 1. The age and gender of survivors and fatal
cases were comparable. Fatal cases had a higher
mean APACHE II (Acute Physiology andChronic Health
Evaluation) score than survivors. Diabetes mellitus
wasapreexisting illness in 12/30 (40%)of thepatients
studied. A similar percentage of diabetics was found
in the survivor and nonsurvivor groups. All the deaths
occurred in the patients with bacteremia and in the
population with pneumonia without bacteremia.
Similar numbers of survivors and fatal cases suffered
acute renal failure, but shock and liver function test
abnormalities occurred more frequently in the fatal
cases.
Protein C and protein S antigen levels, plus
antithrombin activities, for fatal cases and survivors
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Table 1 Demographics and baseline characteristics of study patients.
Survivors (%) (n = 18) Fatal cases (%) (n = 12) Total (%) (n = 30)
Mean APACHE II score (range) 12 (0—19) 22 (17—30) 16 (0—30)
Mean age in years (range) 52 (28—74) 53 (32—82) 53 (28—82)
Gender
Males 12 (67) 7 (58) 19 (63)
Females 6 (33) 5 (42) 11 (37)
Preexisting illness
Diabetes mellitus 7 (39) 5 (42) 12 (40)
Chronic renal disease 1 (5.5) 1 (8) 2 (7)
Site of infection
Bacteremia (with or without primary site) 5 (28) 9 (75) 14 (47)
Lung 6 (33) 3 (25) 9 (30)
Soft tissue 3 (17) 0 3 (10)
Spleen 1 (5.5) 0 1 (3)
Eye 1 (5.5) 0 1 (3)
Unconfirmed 2 (11) 0 2 (7)
Organ failure
Shock 3 (17) 8 (67) 11 (37)
Acute renal failure 5 (28) 4 (33) 9 (30)
Liver function test abnormalities 8 (44) 10 (83) 18 (60)
Table 2 Comparison of baseline and average endothelial modulator markers in survivors and fatal cases (logistic
regression).
Assay Outcome Number Baseline mean  SD p Value Average mean  SD p Value
Protein C (% antigen) Died 12 43.4  18 0.009 39.7  13.8 0.004
Survived 18 74.6  27.8 80.7  26.9
Protein S (% antigen) Died 12 65.7  17.9 0.01 61.8  16.1 0.006
Survived 18 89.0  18.6 87.2  17.4
Antithrombin (% activity) Died 12 71.0  20 0.02 63.5  15.4 0.005
Survived 17 90.4  28.0 94.8  25.6
Figure 1 Protein C antigen levels over time in melioi-
dosis patients, survivors and nonsurvivors. The dashed line
represents the approximate level of protein C (60%)
demarcating survivors from nonsurvivors.are shown in Table 2. Protein C antigen levels and
antithrombin activities for fatal cases and survivors
are shown in Figures 1 and 2 respectively. The mean
baseline protein C antigen levels, protein S levels
and antithrombin activity levels for all cases were
62.1% (standard deviation (SD) 28.6%), 79.7% (SD
21.5%), and 82.4% (SD 26.5%), respectively. Baseline
values of protein C, protein S, and antithrombin
were predictive of poor outcome, with significantly
lower levels found in fatal cases than in survivors
(Table 2; p = 0.009, 0.01 and 0.02, respectively).
When values of these parameters were averaged for
patients during the course of the illness, low protein
C antigen levels, protein S antigen levels, and
antithrombin activities continued to be predictive
of a poor outcome (Table 2). On average, the levels
of protein C, protein S and antithrombin were lower
in the bacteremic patients compared with patients
with a focal site of infection without bacteremia
(data not shown).
The median plasma IL-6 concentration was
240.2 pg/mL (range 14.6—745 000 pg/mL, inter-quartile (IQ) range 64.9—1646.5 pg/mL). Both pro-
tein C and antithrombin values but not protein S
were correlated inversely with IL-6 levels (protein
C: Spearman correlation coefficient 0.74,
p = 0.0001; antithrombin: Spearman correlation
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Figure 2 Antithrombin levels over time in melioidosis
patients, survivors and nonsurvivors. The dashed line
represents the approximate level of antithrombin (70%)
demarcating survivors from nonsurvivors.coefficient 0.68, p = 0.0001; protein S: Spearman
correlation coefficient 0.32, p = 0.077). Baseline
D-dimer levels were significantly higher in fatal
cases than survivors (12.50  11.1 mg/mL and
5.3  10.3 mg/mL, respectively, p = 0.004 by
ANOVA). Both protein C antigen and antithrombin
activities were correlated inversely with D-dimer
levels ( p = 0.005 and 0.0065, respectively). Protein
C and antithrombin levels were also highly corre-
lated in these patients (R = rho = Pearson correla-
tion coefficient = 0.82, p = 0.0001).
Discussion
Acute septicemicmelioidosis is a homogenous formof
Gram-negative sepsis, with a mortality of 35—45%. A
study of proinflammatory cytokine levels in patients
with melioidosis demonstrated that both baseline
and peak TNF-alpha levels were inversely correlated
with time to death. IL-6 concentrations have prog-
nostic value.9 Autopsy findings in patients who died
from acute septicemic melioidosis have demon-
strated fibrin clots as part of the pathology seen with
the disease. Atisook and Panyathanya reported clin-
icopathologic findings from six autopsies performed
on patients who died from acute septicemic melioi-
dosis.20 The findings in these patients included not
only the diffuse abscesses typical of this infection but
also coagulative tissue necrosis, petechial hemor-
rhages in the skin, lungs, and pericardium, and fibrin
thrombi in the lungs, kidney, and adrenals, which are
indicative of disseminated intravascular coagulation.
Thesedata taken together suggest interplaybetween
inflammation and coagulation in the pathology of this
form of sepsis.
Our study investigated systemic levels of three
naturally occurring endothelial modulators as pre-
dictors of mortality in patients with Gram-negativesepsis. Depletion of protein C, protein S, and antith-
rombin at baseline was predictive of poor outcome.
These findings have not been described previously in
melioidosis. Average baseline levels of protein C
were lower than were protein S and antithrombin
levels in the population studied. Low levels of pro-
tein C, antithrombin, and protein S continued to be
predictive of poor outcome throughout the illness.
For protein C, a demarcation level of 60% of normal
separated the survivors from fatal cases (Figure 1).
For antithrombin, this cut-off is less clear but is just
above 70% of normal (Figure 2). These data, taken
together, suggest that a certain critical level of
endothelial modulators is needed to prevent a
vicious circle of inflammation and coagulation,
which can lead to mortality from sepsis.
Low protein C and antithrombin levels were
inversely correlated with the global marker of
inflammation, IL-6. This finding further implicates
the role of proinflammatory cytokines in the loss of
these endogenous endothelial modulators in sepsis.
Patients who died from melioidosis were found to
have significantly higher levels of the fibrin degra-
dation product D-dimer. Deficiencies in protein C
and antithrombin were associated with higher levels
of D-dimer, implying unchecked fibrin production
and lysis, and suggesting fibrin deposition in the
microcirculation as a mechanism that contributes
to organ failure and death.
This study adds to the accumulating literature
demonstrating the link between inflammation and
coagulation in the septic patient. In a study of 43
adultpatientswhometestablishedcriteria for sepsis,
admission values of antithrombin were significantly
higher in survivors than in fatal cases (76%, range 65—
87, and 64%, range 49—71) and inversely correlated
with TNF-alpha levels.21 Lorente et al. found that
antithrombin and protein C levels, but not protein S
levels, were significantly different in survivors and
fatal cases of septic shock.22 Similar findings in this
populationwereobservedbyFourrieretal.,however,
protein C andantithrombin levels that best predicted
a poor outcome were lower than in our study (<40%
and <50%, respectively).23 These studies observed
normal levels of free protein S that are in contrast to
our findings. In summary, the literature in the hetero-
geneous group with sepsis is in agreement with our
data in suggesting that antithrombin and protein C
levels are predictive of patient outcome in sepsis.
Data are also available on the predictive value
of endothelial modulator levels in homogeneous
populations with specific infectious diseases and
syndromes. Purpura fulminans is a syndrome in
which low levels of endothelial modulators such
as protein C are described. Infants born with
homozygous protein C deficiency suffer life-threa-
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Figure 3 Predicted probability of survival in melioidosis
patients. From logistic model for patients’ average pro-
tein C antigen level predicting outcome (n = 30).
Figure 4 Predicted probability of survival in melioidosis
patients. From logistic model for patients’ average antith-
rombin level predicting outcome (n = 30).tening purpura fulminans in the first few days of
life.24 In a study of 40 children with infectious
purpura fulminans, antithrombin, protein C, and
protein S were all significantly lower in fatal cases
than in survivors ( p < 0.005), with protein C the
most depleted factor.25 In 39 patients with sys-
temic meningococcal disease, Brandtzaeg et al.
found that the fatal cases were unable to achieve
protein C levels three fourths of 55% or antithrom-
bin levels three fourths of 60%.26 In a study of 35
patients with meningococcal septic shock, antith-
rombin and protein C levels were significantly
lower in fatal cases than survivors, with a protein
C level <10% the best predictor of a fatal outcome.
Interestingly, the level of free protein S did not
differ significantly between survivors and fatal
cases and the C4b-binding protein levels were
not exceedingly high.27
Our data in melioidosis confirm the interplay of
inflammation and coagulation in sepsis. Consump-
tion of endothelial modulators is a key feature of
this process. Protein C is the modulator most pro-
foundly affected, followed by antithrombin and less
so by protein S. The lowest levels of these endo-
genous anticoagulants were found in the bacteremic
population, a similar finding to that seen in a het-
erogeneous population with severe sepsis.28
A testable hypothesis that arises from the accu-
mulated data is that therapy with protein C and/or
activated protein C and/or antithrombin could
reduce mortality in melioidosis. It is possible to
construct a fitted probability of survival curve from
our data on protein C levels and antithrombin levels
in melioidosis illustrating this hypothesis (Figures 3
and 4). Protein S therapy is a less attractive target
because patients generally have adequate free pro-
tein S levels during the course of sepsis.29 Further-
more, free protein S is in large molar excess over
protein C or activated protein C levels.
Such hypotheses have been evaluated in two
large Phase III mortality trials in patients with severe
sepsis caused by a diverse array of organisms. A trial
of antithrombin compared with placebo in patients
with severe sepsis revealed no difference in 28-day
all-cause mortality rates (relative risk = 1.004).30
However, a very large Phase III trial comparing
pharmacologic doses (24 mg/kg/h for 96 hours) of
recombinant human activated protein C (drotreco-
gin alfa (activated)) with placebo in patients with
severe sepsis demonstrated a 6.1% absolute reduc-
tion in, and 19.4% relative risk reduction in, the 28-
day all-cause mortality in the treatment arm
( p = 0.005).31 It would be of considerable value,
therefore, to conduct such a sepsis trial in disease
caused by a single organism, such as melioidosis or
meningococcal sepsis.The results reported here demonstrate the cen-
tral role of inflammation and coagulopathy in the
pathophysiology of severe sepsis caused by B. pseu-
domallei and the importance of activated protein C
as a mediator of this process. If the substantial
mortality still seen in acute melioidosis is to be
reduced, clinical trials of agents such as activated
protein C or antithrombin replacement therapy
must be conducted soon.
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